Tracking PrEP Rollout & Learning Lessons

Accelerating the rollout of the full range of proven HIV prevention options depends on learning from what’s been done in the past and investing in coordination and innovation to put improved solutions in place. The Biomedical Prevention Implementation Collaborative (BioPIC) is doing just that. Over the last two years, BioPIC—a project led by AVAC with support from the Gates Foundation—has been gathering and sharing evidence on these critical lessons to ensure the next generation of HIV prevention products reaches everyone who needs and wants them with much greater speed and equity.  

What We’re Learning—Highlights from 2024 Convenings

An ongoing series of think tanks, convened by BioPIC and WHO since 2021, are generating key insights for people-centered product delivery. Below, read the latest reports from these think tanks that are informing decision-making on priorities for accelerating access to PrEP. Go to the BioPIC’s page on PrEPWatch to find reports on all think tanks since 2021.  

  • Early Insights from EBONI and PILLAR, February 2024: Early insights from ViiV Healthcare, the manufacturer of CAB for PrEP, from two CAB for PrEP implementation studies, EBONI and PILLAR. Conducted by ViiV in the US, these are among the first studies gathering data in real-world settings. Learn more
  • Taking Stock of PrEP Evidence, March 2024: An analysis of current data and priority evidence gaps. This inquiry was not focused on any one PrEP product, and its findings are informing the focus of future think tanks. Learn more
  • Linking Modellers with the Latest Implementation Science Evidence, March 2024: A consideration of the latest modelling data and insights on injectable cabotegravir (CAB) for PrEP. Read about the biggest takeaways from CAB for PrEP modelling here, and learn more about the big questions that require further inquiry here
  • Discussing Early Results from the SEARCH Dynamic Choice Study, April 2024: Professor Moses Kamya of Makerere University shares early insights from the SEARCH Dynamic Choice Study in Kenya and Uganda, which gave participants a choice between oral PrEP, PEP, and CAB for PrEP, and analyzes the role of choice in PrEP coverage. Watch here
  • PrEP and the Role of HIV Self-Testing, May 23: Highlights from the WHO guidance on use of self-testing (HIVST) as an innovative way to increase PrEP access and coverage and further simplify PrEP delivery. Panelists also share experiences with procurement, costing, rollout and scale-up. Watch Here

As other new biomedical HIV prevention products roll out, BioPIC will continue to hold strategic convenings, identify and address evidence gaps, and work to accelerate equitable product introduction. To learn more efforts to coordinate the introduction of CAB for PrEP, check out the JIAS article Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC). To learn what’s needed to better coordinate rollout for not-yet-approved products in Phase III clinical trials, check out BioPIC’s Adaptable Product Introduction Framework

We hope you will book mark these resources, and stay up to date on findings from future think tanks and webinars in 2024 on the BioPIC page of PrEPWatch.

What’s Next for the Pandemic Accord? A civil society and communities perspective

This side event, co-sponsored with Care and Frontline AIDS, was part of the World Health Assembly and featured expert panelists discussing what’s promising in the Pandemic Accord, what we expect from governments, and what’s missing for successful implementation. Selected panelists came from different health areas but all have experience in pandemic prevention, preparedness, and response.

This panel also helped civil society prepare for the coming year and gain capacity to meaningfully engage in advocacy around implementation of the Accord.

Watch the recording.

Avac Event

The GPP Body of Evidence: GPP Monitoring and Evaluation Frameworks, REAL and REAL2

GPP is an essential part of clinical trials research, and an ethical imperative to creating equitable and effective clinical trials. GPP is created by and for communities, so it necessarily looks different and takes multiple forms in different cultural contexts. This kind of responsiveness is inherent to GPP, but it also makes it difficult to measure and evaluate.

In this webinar, we learned from the Realist Review of Community Engagement and the REAL2 review of participatory research that both examined frameworks for evaluating community engagement efforts, as well as the Global Health Network’s new course on evaluation, and other evaluation efforts in the field of GPP.

Moderator:

  • Jessica Salzwedel, AVAC

Panelists:

  • Alun Davies, The Global Health Network
  • Sassy Molyneux, KEMRI-Wellcome Trust
  • Dr. Robin Vincent, Oxford University

Recording / Alun Davies Slides / Sassy Molyneux Slides / Dr. Robin Vincent Slides

Avac Event

It’s Not Just about the Trial: GPP from discovery to delivery in TB research

GPP enhances every stage of the research lifecycle. In this webinar, our partners at TB Alliance, SMART4TB, and THINK will shared experiences, lessons learned, and innovative approaches in integrating GPP at the organizational, network and situational level, from drug development through delivery.

Moderators:

  • Stacey Hannah, AVAC
  • Dr. Michele Tameris, University of Cape Town

Panelists:

  • Stephanie Seidel, TB Alliance
  • Erica Lessem, SMART4TB
  • Masingita Lambane, THINK

Recording / Stephanie Seidel Slides / Erica Lessem Slides / Masingita Lambane Slides

Fighting the Same Fight Again

Civil Society and Community Engagement in Global Health Initiatives
Authors: Samantha Rick (AVAC), Quentin Batreau (GFAN), Eolann MacFadden (Frontline AIDS)

Pandemic Accord negotiations have so far failed to effectively engage advocate and civil society voices. With key parts of the Pandemic Accord moving toward further negotiation over the next few years, the Coalition of Advocates for Global Health and Pandemic Preparedness calls on advocates in and around the World Health Assembly to continue to rally for meaningful engagement with civil society and community and leadership roles for both in the ongoing multilateral process for pandemic prevention, preparedness, and response (PPPR).

For decades civil society and community organizations have been recognised and legitimately engaged as vital stakeholders and leaders in the HIV response. But this principle of inclusion has been inadequately upheld in other health areas, and vitally important initiatives, including the negotiations of the Pandemic Accord, have failed to build on the success of the HIV response and fully utilize existing models and mechanisms for engagement. Without them, these efforts exclude critical stakeholders when they should integrate civil society organizations (CSOs) as a crucial driver of policy and programming. Although certain initiatives have created some opportunities for CSO involvement, organized campaigns and public outcry have been necessary to garner a seat at the table. With every new program, fund, or secretariat, advocates are compelled to engage in the same repetitive battle to obtain a minimum of two voting seats and consultation prior to decision-making.

Civil society representation at the World Health Assembly has been reduced, a formal mechanism for engagement at UN High Level Meetings has been rejected, requests for even observer status during Pandemic Accord negotiations have also been rejected, and civil society and community advocates have experienced hostility at international convenings such as International Conference on AIDS and STIs in Africa (ICASA). Preventing, preparing, and responding to disease outbreaks requires public trust, understanding of regional or cultural ways of working, geographical limitations, and the true needs of communities. We cannot build effective health infrastructure by erecting barriers to civil society and community leadership. 

It is absolutely crucial that civil society and communities band together to demand meaningful engagement in the processes that follow and refuse to permit governments and institutions from rolling back CSO access and decision-making power even further. 

We have seen throughout the 40 years of the HIV/AIDS response that meaningful engagement  turns the tide when biomedical innovations fall short of their potential because of real-world challenges. Decision makers, government representatives, and multilateral institutional leaders must enshrine a baseline level of meaningful civil society engagement practices where and when international decisions are made. As lessons from the global HIV response show us, it is possible, if not probable, that many of the outstanding issues in the Pandemic Accord could have been solved with civil society input and influence, as knowledge-brokers who bring unique insights, find solution, and foster trust where it’s needed most.

The Coalition of Advocates for Global Health and Pandemic Preparedness is a group of organizations advocating for an integrated and holistic approach to preparedness that emphasizes equity, inclusion, and synergies of multiple global health programs in advancing preparedness. We believe that all global health initiatives should be centered on the key principles of community leadership, equity, access, and human rights and that efforts to fight current epidemics and strengthen health systems are central to equitable pandemic preparedness.

The biggest lesson from the fight against HIV, TB, and malaria is that if space is not reserved for civil society, we must take it – “Nothing For Us Without Us”. Join us at the World Health Assembly or watch the recording of our side event focused on civil society engagement if you can’t make it to Geneva, and keep demanding meaningful engagement in every global health initiative.

Avac Event

Illinois PrEP Summit 2024: Disrupting Disparities and Advancing Access

The conference focuses on advancing biomedical HIV prevention to help achieve Getting to Zero by 2030. Key summit goals include improving access, addressing disparities, fostering research and promoting community engagement. Join us for in-person sessions covering strategies, policies and implementation research.

This conference is curated by AFC, MATEC, PrEP4Teens and Project VIDA.

Registration closes, June 7, 2024.

Avac Event

Using the COMPASS Campaign Advocacy Assessment Tool (C-CAAT) to assess the effectiveness of advocacy campaigns

This webinar is for all COMPASS coalition members, partners, stakeholders and individuals taking on advocacy in various fields.

By the end of the webinar participants are expected to have an improved capacity on how to reflect on advocacy outcomes (positive and negative) individually and collectively with relevant stakeholders and partners; enhanced ability to identify, describe and document advocacy outcomes in a clear and structured manner; and an improved capacity to identify follow up actions/tactics needed to achieve the advocacy goal or respond in the event of a setback.

Avac Event

HIV, Viral Hepatitis and Sexually Transmitted Infections: Progress and gaps

13:00 – 14:30 CEST PM

Please join this webinar being held in the run up to the 77th World Health Assembly.

The World Health Organization (WHO) will launch a publication, which describes progress and gaps identified during the first two years of implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections (STIs) for 2022-2030.

Moderators will ask key leaders in the responses to HIV, viral hepatitis and STIs how we can increase visibility, political will and community activism to accelerate action.

Panelists include:

  • Jérôme Salomon, WHO, Switzerland
  • Jessica Hicks, World Hepatitis Alliance, United Kingdom
  • Maureen Luba, AVAC, Malawi
  • Meg Doherty, WHO, Switzerland
  • Patty Garcia, Cayetano Heredia University, Peru
  • Philippe Duneton, Unitaid, Switzerland
  • Sabin Nsanzimana, Ministry of Health, Rwanda (TBC)

The conversation will be moderated by Charles Gore from the Medicines Patent Pool (MPP) and Birgit Poniatowski from IAS – the International AIDS Society.

The webinar is organized by IAS – the International AIDS Society – and its partners, WHO, Medicines Patent Pool and Unitaid.

Avac Event

What’s Next for the Pandemic Accord? A civil society and communities perspective

13:30-15:00PM Geneva Time

This side event featured expert panelists discussing what’s promising in the Pandemic Accord, what we expect from governments, and what’s missing for successful implementation. Selected panelists came from different health areas but all have experience in pandemic prevention, preparedness, and response.

This panel also helped civil society prepare for the coming year and gain capacity to meaningfully engage in advocacy around implementation of the Accord. 

This event was co-sponsored with Care and Frontline AIDS. This in-person meeting will be recorded and the recording will be posted on this page following the event.

Diversity, Equity and Access to HIV Research

On May 2, 2024, AVAC staffer Jessica Salzwedel gave a presentation on diversity, equity and access in HIV research at the Ending the HIV Epidemic Conference at Weill Cornell Medicine. Check out the full presentation in PDF format.

“When we think about what engagement is important for research, it involves building systems of trust.” – Jessica Salzwedel